Le Thi Tuyet Lan

Le Thi Tuyet Lan

Auto-generated profile, based on publicly available information

Le Thi Tuyet Lan

University of Medicine and Pharmacy Hochiminh City Vietnam

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in Allergy
Verified
Journal Article
Open access
Jean BousquetJean Bousquet
Jean Bousquet
EME. Melén
E. Melén
THT. Haahtela
T. Haahtela
GKG. H. Koppelman
G. H. Koppelman
ATAlkis Togias
Alkis Togias
Josep M. BoquéJosep M. Boqué
Josep M. Boqué
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.

1 January 2020 in Asia Pacific Allergy
Verified
Journal Article
Open access
RPRuby Pawankar
Ruby Pawankar
JWJiu-Yao Wang
Jiu-Yao Wang
I-Jen WangI-Jen Wang
I-Jen Wang
FTFrancis Thien
Francis Thien
YCYoon-Seok Chang
Yoon-Seok Chang
Jae-Won OhJae-Won Oh
Jae-Won Oh
Pawankar R, et al. Asia Pac Allergy. 2020 Jan;10(1):e11. https://doi.org/10.5415/apallergy.2020.10.e11

1 January 2021 in Asia Pacific Allergy
Verified
Journal Article
Open access
PDF file
HNHo Lam Nguyen
Ho Lam Nguyen
NNNguyen-Thanh Nam
Nguyen-Thanh Nam
VLVu Le-Thuong
Vu Le-Thuong
NNNhu Vinh Nguyen
Nhu Vinh Nguyen
LTLe-Thi Tuyet-Lan
Le-Thi Tuyet-Lan
Background: Stepping down treatment for well-controlled mild asthma is challenging to clinicians. The step-down strategy using regularly-intermittent low-dose inhaled corticosteroid has been applied at the University Medical Center (UMC) of Ho Chi Minh City, called as “UMC” approach. Objective: This study aimed to evaluate the efficiency of UMC step-down strategy in well- controlled mild asthma. Methods: A real-world retrospective descriptive study was conducted at UMC from 2009 to 2018. All asthmatic patients (age ≥ 12) who received step-down therapy using this UMC approach were evaluated. Results: Among 2,072 asthma patients to be treated with UMC step-down strategy, only 112 subjects were eligible. The median age was 38.5 years and female was 62.5%. Most patients at their initial presentation were indicated step 4 treatment (87.5%). The controller medications before initiation of UMC treatment included fluticasone propionate 125 μg once-daily, salmeterol/fluticasone propionate 25/125 μg once-daily, and formoterol/budesonide 4.5/160 μg once-daily. After being treated with the UMC approach, the rates of well-controlled asthma ranged from 67.6% to 91.1%. During 1 year with UMC treatment, pulmonary function remained stable and only 7 subjects (6.3%) developed exacerbation. Conclusion: The UMC step-down treatment for well-controlled mild asthma was relatively efficient in maintaining asthma control, stabilization of pulmonary function, and reducing risk of severe exacerbation.

3 August 2021 in Respirology
Verified
Journal Article
Open access
PDF file
HNHo Lam Nguyen
Ho Lam Nguyen
NNNhu Vinh Nguyen
Nhu Vinh Nguyen
YCYoon-Seok Chang
Yoon-Seok Chang
Anh Tuan Dinh-XuanAnh Tuan Dinh-Xuan
Anh Tuan Dinh-Xuan
TLTuyet‐Lan Le‐Thi
Tuyet‐Lan Le‐Thi
Click on the article title to read more.